AMAG-423-201: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Preeclampsia Save

Date Added
August 13th, 2019
PRO Number
Pro00089350
Researcher
Scott Sullivan

List of Studies


Profiles_link
Keywords
Obstetrics and Gynecology
Summary

This study aims to show the safety and effectiveness of AMAG-423, an IV medication, in women with severe preeclampsia. The purpose of this study is to see how well AMAG-423 might work to prevent some of the most serious complications in premature babies, as well as improve symptoms of preeclampsia. Women will be admitted with this diagnosis and receive IV medication, AMAG-423, every 6 hours for up to 4 days. Subjects will be followed through out their hospital stay and up until their post partum 6 week check. The only treatment for severe preeclampsia is delivery.

Institution
MUSC
Recruitment Contact
Jesslyn Payne
843-792-9302
paynej@musc.edu

Change_preferences

-- OR --

Create_login